MECHANISM OF ACTION
Thymosin Alpha-1 is a 28-amino acid peptide originally found in the thymus gland (the organ that trains your immune system, located in your chest). It acts as an immune system balancer rather than a simple booster. When the immune system is too weak, such as in chronic viral infections or after cancer treatment, it helps strengthen the response. When immune cells are overreacting (as in some autoimmune conditions), it helps bring things back to balance. It does this by helping a type of immune cell called a dendritic cell (which acts like a battlefield commander for immune responses) mature properly and direct the right type of attack. It's one of the most extensively studied peptides in the world, with clinical approval in 37 countries.
RESEARCH APPLICATIONS
- Viral hepatitis B and C immunotherapy (approved)
- Adjuvant immunotherapy in oncology
- Sepsis and critical illness immune reconstitution
- COVID-19 cytokine dysregulation
- Vaccine adjuvant research
RESEARCH HIGHLIGHTS
Hepatitis B Seroconversion
2006Meta-analysis of 9 RCTs (n=726) showed higher HBeAg seroconversion with Tα1 vs. IFN-α monotherapy, with superior tolerability.
Ref: Chan et al., Antiviral Therapy
COVID-19 Mortality Reduction
2022Retrospective cohort (n=3,240): Tα1 treatment associated with reduced 28-day mortality (HR 0.58, p<0.001) and shorter ICU stay.
Ref: Liu et al., J Infect Dis
RESEARCH PROTOCOL NOTES
Chemical Identity
Storage & Stability
Lyophilised: 2–8°C, 24 months. Reconstituted: use within 6 hours - no preservative in approved formulation.
Regulatory Status
Approved in 37+ countries as Zadaxin. Not FDA approved. SA: importable via named patient provisions. Not WADA prohibited.